Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONS-3010 versus Humira in moderate to severe plaque psoriasis
NL-OMON42923Phase 3Not yet recruiting
- Sponsor
- Outlook Therapeutics
- Start
- Sep 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in plaque psoriasis comparing ONS-3010 with Humira (2 arms). Primary endpoint: PASI 75 response rate at Week 17. Planned start Sep 2016; status: not yet recruiting.
02
Drugs
adalimumabONS-3010
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NL-OMON42923.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42923.